Gri Bio, INC. (GRI) — SEC Filings

Overview

Gri Bio, INC. (GRI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEF 14A filed on Dec 29, 2025: GRI Bio, Inc. (GRI) is seeking stockholder approval for a reverse stock split of its common stock, with a proposed ratio ranging from one-for-two to one-for-30. The exact ratio will be determined by the board of directors, which also retains the discretion to abandon the split entirely. This proposa

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 7 bearish, 42 neutral, 1 mixed. The dominant filing sentiment for Gri Bio, INC. is neutral.

Filing Type Overview

Gri Bio, INC. (GRI) has filed 4 DEF 14A, 31 8-K, 3 S-1/A, 3 S-1, 6 10-Q, 1 10-K, 1 8-K/A, 1 DEFA14A with the SEC between May 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• GRI Bio Seeks Shareholder Nod for Reverse Stock Split — DEF 14A · Dec 29, 2025 Risk: medium
  GRI Bio, Inc. (GRI) is seeking stockholder approval for a reverse stock split of its common stock, with a proposed ratio ranging from one-for-two to one-for-30.
• GRI Bio, Inc. Files 8-K for Material Agreement — 8-K · Dec 12, 2025 Risk: medium
  GRI Bio, Inc. filed an 8-K on December 12, 2025, reporting an entry into a material definitive agreement as of December 11, 2025. The filing also includes finan
• 8-K Filing — 8-K · Dec 10, 2025
• GRI Bio Amends S-1, Updates Warrants and Engagement Letter — S-1/A · Dec 10, 2025 Risk: high
  GRI Bio, Inc. filed an S-1/A on December 9, 2025, primarily as an exhibits-only amendment to its Registration Statement (File No. 333-291999). This filing did n
• 8-K Filing — 8-K · Dec 8, 2025
• GRI Bio Launches Equity Offering to Fund IPF Drug Development — S-1 · Dec 8, 2025 Risk: high
  GRI Bio, Inc. (GRI) is undertaking a public offering of up to 5,128,205 shares of common stock and accompanying Series F warrants, with an assumed combined publ
• 8-K Filing — 8-K · Dec 2, 2025
• GRI Bio's Losses Widen Amid Soaring R&D, Cash Dwindles — 10-Q · Nov 14, 2025 Risk: high
  GRI Bio, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $9,297 thousand, compared to $6,259 thousand fo
• GRI Bio, Inc. Files 8-K with Regulatory Updates — 8-K · Aug 20, 2025 Risk: low
  GRI Bio, Inc. filed an 8-K on August 20, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Vallon
• GRI Bio's Losses Widen Amid Increased R&D, Going Concern Doubts Persist — 10-Q · Aug 14, 2025 Risk: high
  GRI Bio, Inc. reported a net loss of $2.892 million for the three months ended June 30, 2025, an increase from $2.250 million for the same period in 2024. For t
• GRI Bio, Inc. Files 8-K: Director Changes, Officer Appointments, and More — 8-K · Aug 13, 2025 Risk: medium
  GRI Bio, Inc. filed an 8-K on August 13, 2025, reporting on several key events. These include the departure of directors or certain officers, the election of ne
• GRI Bio, Inc. Files 8-K — 8-K · Jul 31, 2025 Risk: low
  GRI Bio, Inc. filed an 8-K on July 31, 2025, reporting other events and financial statements. The company, formerly known as Vallon Pharmaceuticals, Inc., is in
• GRI Bio Schedules Virtual 2025 Annual Meeting, Board Backs All Proposals — DEF 14A · Jul 11, 2025 Risk: low
  GRI Bio, Inc. has filed a Definitive Proxy Statement (DEF 14A) on July 11, 2025, for its 2025 Annual Meeting of Stockholders, scheduled for August 13, 2025, at
• GRI Bio, Inc. Files 8-K — 8-K · Jun 26, 2025 Risk: low
  GRI Bio, Inc. filed an 8-K on June 26, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Vallo
• GRI Bio, Inc. Files 8-K — 8-K · May 23, 2025 Risk: low
  GRI Bio, Inc. filed an 8-K on May 23, 2025, reporting other events and financial statements. The company, formerly known as Vallon Pharmaceuticals, Inc. and GRI
• GRI Bio, Inc. Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
  GRI Bio, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Vallon Pharmaceuticals, Inc., is focused on pharmaceutical pre
• GRI Bio, Inc. Files 8-K — 8-K · May 5, 2025 Risk: low
  GRI Bio, Inc. filed an 8-K on May 5, 2025, reporting other events and financial statements. The company, formerly known as Vallon Pharmaceuticals, Inc. and GRI
• GRI Bio, Inc. Reports Change in Certifying Accountant — 8-K · Apr 16, 2025 Risk: low
  GRI Bio, Inc. filed an 8-K on April 16, 2025, reporting changes in its certifying accountant as of April 15, 2025. The company, formerly known as Vallon Pharmac
• GRI Bio, Inc. Files 8-K: Material Agreement & Other Events — 8-K · Apr 2, 2025 Risk: medium
  GRI Bio, Inc. announced on April 1, 2025, that it entered into a Material Definitive Agreement. The company also reported on other events and filed financial st
• GRI Bio, Inc. Files S-1/A for Securities Registration — S-1/A · Mar 26, 2025 Risk: medium
  GRI Bio, Inc. filed an S-1/A on March 26, 2025, to register securities. The company, formerly known as Vallon Pharmaceuticals, Inc. and GRI BIO, Inc., is incorp
• GRI Bio, Inc. Files S-1 for Securities Registration — S-1 · Mar 25, 2025 Risk: medium
  GRI Bio, Inc. filed an S-1 form on March 25, 2025, to register its securities. The company, formerly known as Vallon Pharmaceuticals, Inc. until April 24, 2023,
• GRI Bio Files 8-K on Financials — 8-K · Mar 17, 2025 Risk: low
  GRI Bio, Inc. filed an 8-K on March 17, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The
• 10-K Filing — 10-K · Mar 14, 2025
• GRI Bio Faces Delisting Concerns — 8-K · Mar 11, 2025 Risk: high
  GRI Bio, Inc. filed an 8-K on March 10, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The company, formerly known as Vall
• GRI Bio, Inc. Files 8-K with Corporate Amendments — 8-K · Feb 19, 2025 Risk: medium
  On February 19, 2025, GRI Bio, Inc. filed an 8-K report detailing several key events. The company announced amendments to its articles of incorporation and byla
• GRI Bio, Inc. Files 8-K on Security Holder Votes — 8-K · Feb 11, 2025 Risk: low
  GRI Bio, Inc. filed an 8-K on February 11, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's corporate ac
• GRI Bio Files Definitive Proxy Statement — DEF 14A · Jan 17, 2025 Risk: low
  GRI Bio, Inc. filed a definitive proxy statement (DEF 14A) on January 17, 2025, for its fiscal year ending December 31, 2024. The company, formerly known as Val
• GRI Bio, Inc. Files 8-K — 8-K · Dec 20, 2024 Risk: low
  GRI Bio, Inc. filed an 8-K on December 20, 2024, reporting other events and financial statements. The company, formerly known as Vallon Pharmaceuticals, Inc. an
• GRI Bio, Inc. Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: high
  GRI Bio, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported a net loss for the nine months ended September 30, 2024, and its cas
• GRI BIO, Inc. Files 8-K — 8-K · Oct 24, 2024 Risk: low
  GRI BIO, Inc. filed an 8-K on October 24, 2024, reporting other events and financial statements. The company, formerly known as Vallon Pharmaceuticals, Inc., is
• GRI BIO, Inc. Files 8-K on Material Agreements & Equity Sales — 8-K · Oct 22, 2024 Risk: medium
  GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed an 8-K on October 22, 2024, reporting on several events as of October 21, 2024. These include enteri
• GRI BIO, Inc. Files 8-K/A Amendment on Listing Status — 8-K/A · Sep 11, 2024 Risk: medium
  GRI BIO, Inc. filed an amendment (8-K/A) on September 11, 2024, regarding a notice of delisting or failure to satisfy continued listing rules. This filing relat
• GRI BIO, Inc. Files 8-K on Security Holder Votes — 8-K · Sep 6, 2024 Risk: low
  GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed an 8-K on September 6, 2024, to report on matters submitted to a vote of its security holders. The c
• GRI BIO, Inc. Files 8-K on Security Holder Votes — 8-K · Aug 23, 2024 Risk: low
  GRI BIO, Inc. filed an 8-K on August 23, 2024, to report on matters submitted to a vote of its security holders. The company, formerly known as Vallon Pharmaceu
• GRI BIO Files Proxy Statement Supplement — DEFA14A · Aug 16, 2024 Risk: low
  GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed a Definitive Additional Materials (DEFA14A) document on August 16, 2024. This filing supplements the
• GRI BIO, Inc. Files Q2 2024 10-Q — 10-Q · Aug 14, 2024 Risk: medium
  GRI BIO, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly Vallon Pharmaceuticals, Inc., reported financial results for the second
• GRI BIO, Inc. Files Definitive Proxy Statement — DEF 14A · Aug 2, 2024 Risk: low
  GRI BIO, Inc. filed its definitive proxy statement on August 2, 2024, for its annual meeting of stockholders. The company, formerly known as Vallon Pharmaceutic
• GRI BIO, Inc. Files 8-K — 8-K · Jul 26, 2024 Risk: low
  GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed an 8-K on July 26, 2024, to report other events and financial statements. The company, incorporated
• GRI BIO, Inc. Files 8-K for Other Events — 8-K · Jul 19, 2024 Risk: low
  GRI BIO, Inc. filed an 8-K on July 19, 2024, to report other events and financial statements. The company, formerly known as Vallon Pharmaceuticals, Inc. until
• GRI BIO Faces Delisting Concerns — 8-K · Jul 8, 2024 Risk: high
  GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed an 8-K on July 8, 2024, reporting a notice of delisting or failure to satisfy continued listing rule
• GRI BIO, Inc. Files 8-K for Material Definitive Agreement — 8-K · Jun 27, 2024 Risk: medium
  GRI BIO, Inc. announced on June 26, 2024, that it entered into a Material Definitive Agreement. The company, formerly known as Vallon Pharmaceuticals, Inc., is
• GRI BIO, Inc. Amends S-1 Filing — S-1/A · Jun 26, 2024 Risk: medium
  GRI BIO, Inc. filed an S-1/A on June 26, 2024, to amend its registration statement. The company, formerly Vallon Pharmaceuticals, Inc., is based in La Jolla, CA
• GRI BIO, Inc. Files S-1 for Security Registration — S-1 · Jun 20, 2024 Risk: medium
  GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed an S-1 form on June 20, 2024, to register securities. The company, incorporated in Delaware with its
• GRI BIO, Inc. Reports Director/Officer Changes — 8-K · Jun 18, 2024 Risk: medium
  GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed an 8-K on June 17, 2024, reporting on the departure of directors, election of new directors, appoint
• GRI BIO, Inc. Files 8-K on Security Holder Rights — 8-K · Jun 14, 2024 Risk: medium
  GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed an 8-K on June 13, 2024, reporting material modifications to the rights of security holders, amendme
• GRI BIO, Inc. Files 8-K on Security Holder Vote Matters — 8-K · Jun 7, 2024 Risk: low
  GRI BIO, Inc. filed an 8-K on June 7, 2024, to report on the submission of matters to a vote of security holders. The company, formerly known as Vallon Pharmace
• GRI BIO Faces Delisting Concerns — 8-K · May 22, 2024 Risk: high
  GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed an 8-K on May 22, 2024, reporting a notice of delisting or failure to satisfy a continued listing ru
• GRI BIO, Inc. Enters Material Definitive Agreement — 8-K · May 20, 2024 Risk: medium
  GRI BIO, Inc. announced on May 20, 2024, that it entered into a Material Definitive Agreement. The company, formerly known as Vallon Pharmaceuticals, Inc., is i
• GRI BIO, Inc. Files 8-K on Operations and Financials — 8-K · May 13, 2024 Risk: low
  GRI BIO, Inc. filed an 8-K on May 13, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures a
• GRI BIO, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 10, 2024 Risk: low
  GRI BIO, Inc. (GRI) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. GRI BIO, Inc. filed a 10-Q report for the period ending March 31, 2024. The co

Risk Profile

Risk Assessment: Of GRI's 46 recent filings, 8 were flagged as high-risk, 17 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Gri Bio, INC.'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: N/A
• Net Income: $ -9,297 thousand
• EPS: $ -5.19
• Debt-to-Equity: N/A
• Cash Position: $ 4,055 thousand
• Operating Margin: N/A
• Total Assets: $ 4,782 thousand
• Total Debt: N/A

Key Executives

• W. Marc Hertz, Ph.D.
• Leanne Kelly
• David Szekeres
• David Baker
• Roelof Rongen
• Board of Directors

Industry Context

GRI Bio, Inc. operates in the biotechnology sector, a highly competitive and capital-intensive industry. Companies in this space often face significant challenges in drug development, regulatory approval, and securing funding. The need for a reverse stock split to maintain Nasdaq listing suggests potential pressures related to market valuation and investor confidence, common themes for smaller or development-stage biotech firms.

Top Tags

pharmaceuticals (10) · corporate-governance (8) · financials (7) · Biotechnology (6) · 8-K (6) · corporate-filing (5) · sec-filing (5) · material-agreement (4) · 10-Q (4) · delisting (4)

Key Numbers

• Shares of common stock outstanding: 10,121,060 — Entitled to vote at the Special Meeting as of December 19, 2025
• Reverse stock split ratio range: 1-for-2 to 1-for-30 — Proposed range for the Amendment Proposal
• Special Meeting Date: January 15, 2026 — Date stockholders will vote on the reverse stock split
• Record Date: December 19, 2025 — Date to determine eligible voters for the Special Meeting
• Proxy solicitation fee: $8,500 — Paid to Campaign Management, LLC for services
• SEC File Number: 001-40034 — Identifies the company's filing with the SEC
• IRS Employer Identification No.: 82-4369909 — Company's tax identification number
• Registration Statement File Number: 333-291999 — Identifies the specific S-1 filing being amended.
• Filing Date: 2025-12-09 — Date the S-1/A was filed with the SEC.
• Engagement Letter Amendment Date: 2025-12-05 — Date the engagement letter with H.C. Wainwright Co., LLC was amended.
• Original Engagement Letter Date: 2024-10-21 — Date of the initial engagement letter with H.C. Wainwright Co., LLC.
• Shares of Common Stock and Series F Warrants offered: 5,128,205 — Represents the maximum number of units offered in the primary offering.
• Assumed combined public offering price: $1.95 — Last reported sale price of Common Stock on Nasdaq on December 2, 2025, used for illustrative purposes.
• Pre-Funded Warrants offered: 5,128,205 — Maximum number of pre-funded warrants available for purchasers exceeding beneficial ownership thresholds.
• Pre-Funded Warrant exercise price: $0.0001 — Nominal exercise price for pre-funded warrants, reducing upfront cash outlay for investors.

Related Companies

GRIB

Frequently Asked Questions